SWTX — SpringWorks Therapeutics Share Price
0.000.00%
Last trade - 00:00- $3.35bn
- $3.05bn
- $191.59m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 6.97 | ||
| Price to Tang. Book | 6.97 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 17.5 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -57.08% | ||
| Return on Equity | -46.62% | ||
| Operating Margin | -145.17% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 35 | n/a | n/a | 5.45 | 191.59 | 350.05 | 591.63 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer. The Company developed and is commercializing OGSIVEO (nirogacestat) as a Food and Drug Administration (FDA)-approved medicine for adults with desmoid tumors and GOMEKLI (mirdametinib) as an FDA-approved medicine for both adults and children with neurofibromatosis type I associated plexiform neurofibromas (NF1-PN). It is also advancing a diverse portfolio of novel targeted therapy product candidates for patients with both solid tumors and hematological cancers. Brimarafenib is an investigational oral, small molecule, next-generation RAF dimer inhibitor that the Company is advancing in the clinic. SW-682 is an investigational oral, small molecule TEA Domain (TEAD), inhibitor that is evaluating in Hippo-mutant solid tumors. SW-3431 is an investigational, potentially first-in-class, small molecule activator of Protein Phosphotase 2A (PP2A), complexes.
Directors
- Daniel Lynch NEC (62)
- Saqib Islam CEO (51)
- Francis Perier CFO (61)
- Badreddin Edris COO (34)
- Daniel Pichl CHO (38)
- Herschel Weinstein GCN (65)
- Stephen Squinto OTH (64)
- Bhavesh Ashar OTH (55)
- James Cassidy OTH
- L. Mary Smith OTH (54)
- Alan Fuhrman IND (64)
- Julie Hambleton IND (63)
- Freda Lewis-Hall IND (66)
- Jeffrey Schwartz IND (42)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- March 20th, 2019
- Public Since
- September 13th, 2019
- No. of Shareholders
- 10
- No. of Employees
- 368
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 74,984,358
- Address
- 100 Washington Blvd, STAMFORD, 06902-9302
- Web
- https://www.springworkstx.com/
- Phone
- +1 2038839490
- Auditors
- Ernst & Young LLP
Upcoming Events for SWTX
SpringWorks Therapeutics Inc Annual Shareholders Meeting
SpringWorks Therapeutics Inc Annual Shareholders Meeting
Q2 2025 SpringWorks Therapeutics Inc Earnings Release
Similar to SWTX
Alnylam Pharmaceuticals
NASDAQ Global Select Market
Amgen
NASDAQ Global Select Market
Amneal Pharmaceuticals
NASDAQ Global Select Market
Amphastar Pharmaceuticals
NASDAQ Global Select Market
Apellis Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the SpringWorks Therapeutics share price?
As of Today at 23:24 UTC, shares in SpringWorks Therapeutics are trading at $44.72. This share price information is delayed by 15 minutes.
How has the SpringWorks Therapeutics share price performed this year?
Shares in SpringWorks Therapeutics last closed at $44.72 and the price had moved by +1.18% over the past 365 days. In terms of relative price strength the SpringWorks Therapeutics share price has underperformed the S&P500 Index by -6.61% over the past year.
What are the analyst and broker recommendations for SpringWorks Therapeutics?
The overall consensus recommendation for SpringWorks Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the SpringWorks Therapeutics dividend yield?
SpringWorks Therapeutics does not currently pay a dividend.
Does SpringWorks Therapeutics pay a dividend?
SpringWorks Therapeutics does not currently pay a dividend.
When does SpringWorks Therapeutics next pay dividends?
SpringWorks Therapeutics does not currently pay a dividend.
How do I buy SpringWorks Therapeutics shares?
To buy shares in SpringWorks Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of SpringWorks Therapeutics?
As of the previous close price of $44.72, shares in SpringWorks Therapeutics had a market capitalisation of $3.35bn.
Where are SpringWorks Therapeutics shares listed?
Here are the trading details for SpringWorks Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: SWTX
What kind of share is SpringWorks Therapeutics?
Based on an overall assessment of its quality, value and momentum SpringWorks Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a SpringWorks Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in SpringWorks Therapeutics is $72.50. That is 62.12% above the last closing price of $44.72.
Analysts covering SpringWorks Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$2.37 for the next financial year.
Find out moreWhat is the trend in the SpringWorks Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like SpringWorks Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +60.81%.
As of the last closing price of $44.72, shares in SpringWorks Therapeutics were trading +13.6% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the SpringWorks Therapeutics PE Ratio?
The SpringWorks Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $44.72.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of SpringWorks Therapeutics?
SpringWorks Therapeutics' management team is headed by:
- Daniel Lynch - NEC
- Saqib Islam - CEO
- Francis Perier - CFO
- Badreddin Edris - COO
- Daniel Pichl - CHO
- Herschel Weinstein - GCN
- Stephen Squinto - OTH
- Bhavesh Ashar - OTH
- James Cassidy - OTH
- L. Mary Smith - OTH
- Alan Fuhrman - IND
- Julie Hambleton - IND
- Freda Lewis-Hall - IND
- Jeffrey Schwartz - IND